PUBLIC CONTRACT · 2022
Pq/1651/2022 medicamentos
- Contract value
- €128,242.35
- Signed on
- 2 June 2022
- Procedure
- Ao abrigo de acordo-quadro (art.º 259.º)
This page lays out the fields published on Portal BASE and says when a field is unavailable. It is not an assessment of the contract's merit, legality or impact.
Record 9309603PUBLISHED SUBJECT
PQ/1651/2022 MEDICAMENTOS
Parties involved
- Place of performance
- Portugal, Lisboa, Lisboa
- NUTS region
- Not stated
WHO BID
Awardee and competitors
Companies that IMPIC lists as the awardee and as competitors in this procedure.
- Awardee
- NOVARTIS FARMA-PROD.FARMACÊUTICOS,SA. · Tax ID 500063524
- Bidder
- TEVA PHARMA - PRODUTOS FARMACEUTICOS,LDA · Tax ID 507045491
- Bidder
- Accord Healthcare,Unipessoal Lda · Tax ID 508622263
- Bidder
- HIKMA FARMACÊUTICA (PORTUGAL) SA. · Tax ID 502266791
- Bidder
- FARMOZ-SOC. TÉCNICA-MEDICINAL · Tax ID 501505334
- Bidder
- BRISTOL - MYERS SQUIBB SA. · Tax ID 500048193
- Bidder
- LAB. PFIZER, LDA. · Tax ID 500162166
Values and timeline
- Contract price
- €128,242.35
- Procedure base price
- €742,549.90
- Total effective price
- Not reported on Portal BASE
- Publication date
- 14 June 2022
- Award date
- 31 May 2022
- Signing date
- 2 June 2022
- Performance period
- 214 days
The contract price is the value agreed in the contract, not the amount paid.
Procedure and framework
- Contract type
- Aquisição de bens móveis
- Procedure type
- Ao abrigo de acordo-quadro (art.º 259.º)
- Award criterion
- Monofator
- CPV code
- 33600000-6 - Produtos farmacêuticos
- Legal basis
- Artigo 259.º do Código dos Contratos Públicos
- Regime
- Código dos Contratos Públicos (DL111-B/2017) e Lei n.º 30/2021, de 21.05
- Framework agreement
- CP 2021/6 - Medicamentos do foro oncológico e imunomoduladores
- Centralised procedure
- No
- Environmental criterion
- No
- Notice
- Not stated
- Procedure identifier
- 5920661
Compare with other contracts
Search the same body, supplier, place or type of service to understand the context of the published index.